View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
March 25, 2022updated 11 Jul 2022 1:54pm

Twitter: Philippe Pibarot – cardiac surgery improving survival in patients with TAVI-IE top tweet in February

Clinical Trials Arena lists five of the most popular tweets on cardiology in February 2022 based on data from GlobalData’s Pharmaceuticals Influencer Platform.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The top tweets are based on total engagements (likes and retweets) received on tweets from more than 150 cardiology experts tracked by GlobalData’s Pharmaceuticals Influencer platform during February 2022.

1. Philippe Pibarot’s tweet on the effectiveness of cardiac surgery in improving survival in patients with transcatheter aortic valve implantation-infective endocarditis (TAVI-IE)

Philippe Pibarot, a clinical scientist and professor, tweeted on research showing that surgical intervention in patients with infective endocarditis after transcatheter aortic valve implantation (TAVI-IE) did not improve survival or one-year mortality as compared to medical therapy. In the international registry, a majority of patients with TAVI-IE were treated with antibiotics alone. Cardiac surgery combined with antibiotics did not show improvement in all-cause in-hospital or one-year mortality in patients.

The research paper further detailed that the high death rates of patients with TAVI-IE were related to their individual characteristics, IE-related problems, and pathogen. About 584 patients were investigated, which included 19% or 111 patients treated with cardiac surgery and antibiotics (IE-CS) and 81% or 473 patients treated with antibiotics alone (IE-AB).

Username: Philippe Pibarot

Twitter handle: @PPibarot

Likes: 94

Retweets: 33

2. Pradeep Natarajan’s tweet on the use of evidence-based cardiovascular preventative therapies in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD)

Pradeep Natarajan, director of preventative cardiology at the Massachusetts General Hospital, shared a study on the underutilisation of evidence-based therapies for cardiovascular risk reduction among patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) in the US.

As many as 324,706 patients were evaluated in the study across 12 health systems, and it was found that less than one in 20 patients were given all three evidence-based therapies, including high-intensity statin, either an angiotensin-converting enzyme inhibitor (AECI) or angiotensin-receptor blocker (ARB), and either a sodium-glucose cotransporter-2 inhibitors (SGLT2I) and/or a glucagon-like peptide-1 receptor agonist (GLP-1RA). The findings suggested that multidimensional interventions are required to overcome the barriers to using evidence-based therapies and encourage their best possible use.

Username: Pradeep Natarajan

Twitter handle: @pnatarajanmd

Likes: 74

Retweets: 22

3. Raviele Antonio’s tweet on the corelation between excess daytime sleepiness and increased cardiovascular risk

Raviele Antonio, a cardiologist and president of ALFA – Alliance to Fight Atrial Fibrillation, based in Italy, shared an infographic on plausible mechanisms on how excessive daytime sleepiness can increase the risk of cardiovascular mortality. According to a theoretical framework presented by the researchers, excessive daytime sleepiness is linked to dysbiosis of the gut microbiome, adipose dysfunction, and predispositions/epigenetic changes, which can directly contribute to enhanced cardiovascular risk in individuals reporting excessive sleepiness during the day.

The research further highlighted that sleepiness was measured by the frequency at which individuals felt overly sleepy within a month.

Username: Raviele Antonio

Twitter handle: @drraviele

Likes: 40

Retweets: 15

4. Dr Deepak L Bhatt’s tweet on diagnosing and treating acute coronary syndromes (ACS)

Dr Deepak L Bhatt, a cardiologist at Brigham and Women’s Hospital and VA Boston Healthcare, shared a study on diagnosing and treating ACS, which encompasses a range of disorders characterised by a sudden reduction in the blood flow to the heart. The disorders include non-STEMI (NSTEMI), ST-segment elevation myocardial infarction (STEMI), and unstable angina. The study highlighted that chest discomfort at rest is the most common symptom of ACS, affecting approximately 79% of men and 74% of women with ACS. More than seven million individuals are diagnosed with ACS every year worldwide, among who more than one million are required to be hospitalised in the US alone.

The study further noted that electrocardiography should be performed within ten minutes of observing possible ACS in the patients, which can distinguish between STEMI and non–ST-segment elevation ACS (NSTE-ACS). For people with STEMI, coronary catheterisation, and percutaneous coronary intervention (PCI) within two hours of observing possible ACS reduced mortality. The research also highlighted the importance of quick invasive coronary angiography followed by percutaneous or surgical revascularisation within the next 24 to 48 hours, which helped in reducing the risk of death from 6.5% to 4.9% in high-risk patients with NSTE-ACS and no contraindications.

Username: Dr. Deepak L. Bhatt

Twitter handle: @DLBHATTMD

Likes: 26

Retweets: 13

5. Roger Blumenthal’s tweet on the association of Lp(a) and coronary artery calcification (CAC) with atherosclerotic cardiovascular disease (ASCVD)

Roger Blumenthal, director of the Ciccarone Centre for Prevention of Cardiovascular Disease, shared an article on the joint association of lipoprotein(a) [Lp(a)] and CAC with increased risk of atherosclerotic cardiovascular disease (ASCVD). Researchers observed 476 incident major ASCVD events during 13.2 years of follow-up among asymptomatic participants of the Multi-Ethnic Study of Atherosclerosis (MESA). They found that both Lp(a) and CAC were independently associated with ASCVD risk of death, fatal and non-fatal myocardial infarction (MI), and stroke after adjusting other risk factors such as family history of MI and each other.

The study also noted that no difference was observed in incident ASCVD for people falling within CAC score category zero to less than 100 when the Lp(a) was more than or equal to 50 mg/dL, the level at which Lp(a) is considered to be a risk-enhancing factor. The research also suggested that both Lp(a) and CAC may be used alongside to take primary prevention therapy decisions.

Username: Roger Blumenthal

Twitter handle: @rblument1

Likes: 24 Retweets: 6

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena